Establishing an EGFR mutation screening service for non-small cell lung cancer - Sample quality criteria and candidate histological predictors

European Journal of Cancer

Volumn 48, Issue 1, 2012, Pages 61-67

  Leary, Alexandra F ^a   Castro, David Gonzalez De ^b   Nicholson, Andrew G ^c,d   Ashley, Sue ^a   Wotherspoon, Andrew ^a   O'Brien, Mary E R ^a   Popat, Sanjay ^a,e  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Biopsy; EGFR mutation; Histological predictors; Mutation testing; Non small cell lung cancer; Sample quality

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; THYROID TRANSCRIPTION FACTOR 1;

ARTICLE; DNA CONTENT; EXON; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT SELECTION; PREVALENCE; PRIORITY JOURNAL; QUALITY CONTROL; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SMOKING; TISSUE SECTION; TURNAROUND TIME;

ALGORITHMS; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; FEASIBILITY STUDIES; FEMALE; GENE FREQUENCY; GENES, ERBB-1; GENETIC TESTING; HUMANS; LUNG NEOPLASMS; MALE; MUTATION, MISSENSE; PROGNOSIS; QUALITY CONTROL; RISK FACTORS; SPECIMEN HANDLING;

EID: 83255193971     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.09.022     Document Type: Article

References (18)

1. M.S. Tsao, A. Sakurada, and J.C. Cutz Erlotinib in lung cancer - molecular and clinical predictors of outcome N Engl J Med 353 2005 133 144
2. S.V. Sharma, D.W. Bell, and J. Settleman Epidermal growth factor receptor mutations in lung cancer Nat Rev Cancer 7 2007 169 181
3. D.H. Lee, K. Park, and J.H. Kim Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy Clin Cancer Res 16 2010 1307 1314
4. T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
5. C. Zhou, Y.L. Wu, and G. Chen Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 2011 735 742
6. T. Mitsudomi, S. Morita, and Y. Yatabe Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
7. M. Maemondo, A. Inoue, and K. Kobayashi Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
8. M.A. Molina-Vila, J. Bertran-Alamillo, and N. Reguart A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells J Thorac Oncol 3 2008 1224 1235
9. W. Pao, and M. Ladanyi Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method Clin Cancer Res 13 2007 4954 4955
10. W.D. Travis, E. Brambilla, and H.-K. Muller-Hermelink WHO classification: pathology and genetics. Tumours of the lung, pleura, thymus and heart 2004 IARC Press Lyon, France
11. W.D. Travis, E. Brambilla, and M. Noguchi International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma J Thorac Oncol 6 2011 244 285
12. S.P. D'Angelo, B. Park, and C.G. Azzoli Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center J Thorac Cardiovasc Surg 2010
13. R. Rosell, T. Moran, and C. Queralt Screening for epidermal growth factor receptor mutations in lung cancer N Engl J Med 361 2009 958 967
14. N. Motoi, J. Szoke, and G.J. Riely Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis Am J Surg Pathol 32 2008 810 827
15. J.H. Smouse, E.S. Cibas, and P.A. Janne EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer Cancer Cytopathol 117 2009 67 72
16. S. von Ahlfen, A. Missel, and K. Bendrat Determinants of RNA quality from FFPE samples PLoS One 2 2007 e1261
17. R. Pirker, F.J. Herth, and K.M. Kerr Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop J Thorac Oncol 5 2010 1706 1713
18. R. Penzel, C. Sers, and Y. Chen EGFR mutation detection in NSCLC-assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC Virchows Arch 458 2011 95 98